Breezing

Executive Summary

Breezing is a U.S.-based digital health company that develops and commercializes FDA-cleared portable indirect calorimeters. Its core technology measures resting energy expenditure (REE) and respiratory quotient (RQ) from a patient's breath using a disposable sensor cartridge. The company targets clinical (Breezing Med) and wellness/research (Breezing Pro) markets for weight management, nutritional assessment, and sports science. Founded in 2013 and headquartered in Tempe, Arizona, Breezing provides a non-invasive, accurate metabolic analysis tool that can be used at point of care or remotely. With increasing focus on personalized nutrition and metabolic health, Breezing is well-positioned to address the growing demand for objective metabolic measurements. The company's FDA clearance validates its safety and efficacy, differentiating it from many consumer-grade devices. Despite limited public information on funding or revenue, Breezing's technology has potential applications in obesity management, diabetes care, and athletic performance. Key upcoming catalysts include expansion of clinical indications, strategic partnerships, and new product iterations that could broaden its addressable market. However, the company faces competition from other metabolic rate measurement devices and established indirect calorimetry systems in clinical settings.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation sensor cartridge with improved accuracy70% success
• Q4 2026Partnership with a major telehealth or weight management platform for integrated metabolic monitoring50% success
• TBDPublication of clinical study demonstrating significant weight loss outcomes using Breezing device80% success